Verona Stock Soars After $200m Placement For COPD Drug
Fundraise Nearly Quadruples Market Cap
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
